Data Supplement
- Supplemental Data -
Supplementary Table 1 - Human in vitro data for FMO substrates (Jones et al., 2017)
Supplementary Table 2 - Options used to define the elimination within PBPK platform (Simcyp V16)
Supplementary Figure 1 - Forest plot showing the physiologically based pharmacokinetic modeling performance of FMO substrates using rFMO data with and without scalar (tissue specific or ISEF) in the model
Supplementary Table 3 - Simulated mean (SD) PK parameters for FMO substrates using HLM or rFMO with ISEF or tissue specific scalar data
Supplementary Table 4 - Paediatrics simulations for Itopride using rFMO data
Supplementary Table 5 - Mass Spectrometer parameters for FMO substrates
Supplementary Text